Severe acute respiratory syndrome coronavirus 2 (SARS–CoV-2), the cause of coronavirus
disease 2019 (COVID-19), has spurred a global health crisis. To date, there are no proven …

The efficacy of convalescent plasma for coronavirus disease 2019 (COVID-19) is unclear.
Although most randomized controlled trials have shown negative results, uncontrolled studies …

BACKGROUND: There is little systematically derived evidence‐based guidance to inform
plasma transfusion decisions. To address this issue, the AABB commissioned the …

Heparin-induced thrombocytopenia and thrombosis (HITT) is a severe complication of heparin
therapy caused by antibodies to complexes between unfractionated heparin (UFH) and …

Heparin-induced thrombocytopenia/thrombosis (HIT/HITT) is a severe, life-threatening
complication that occurs in 1% to 3% of patients exposed to heparin. Interactions between heparin…

High-dose granulocyte transfusion therapy has been available for 20 years, yet its clinical
efficacy has never been conclusively demonstrated. We report here the results of RING (…

Emerging evidence supports a role for platelets in the progression of atherosclerosis in addition
to an involvement in thrombotic vascular occlusion. Platelet Factor 4 (PF4), a chemokine …

Activated platelets release their granule content in a concentrated fashion at sites of injury.
We examined whether ectopically expressed factor VIII in developing megakaryocytes would …

Accumulation of low-density lipoprotein (LDL)-derived cholesterol by macrophages in
vessel walls is a pathogenomic feature of atherosclerotic lesions. Platelets contribute to lipid …

Activated platelets, which release platelet factor 4 (PF4) are present in patients with atherosclerosis.
To date, no direct invivo evidence exists for the involvement of PF4 in atherogenesis…